SEC Form 4 · accession 0001140361-17-014170
CytomX Therapeutics, Inc. · CTMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marion McCourt
Director
Period of report
Mar 29, 2017
Accepted (ET)
Mar 31, 2017 · 2:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001501989
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $17.00 | Mar 29, 2017 | A | 28,000 | A | — | Mar 28, 2027 | Common Stock | 28,000 | 28,000 | D |
Explanation of responses
- F11/36th of the shares subject to the option vest on each monthly anniversary measured from March 31, 2017 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.